← FDA DRUG APPROVALS

FDA ANDA · ANDA062413

GENTAMICIN SULFATE

Sponsor: ABBOTT

APPLICATION
ANDA062413
TYPE
ANDA
ORIGINAL APPROVAL
1983-08-11
LATEST ACTION
1993-07-14
ROUTE
INJECTION
DOSAGE FORM
INJECTABLE
MARKETING STATUS
Discontinued

Products

GENTAMICIN SULFATEDiscontinued
GENTAMICIN SULFATE EQ 1.4MG BASE/ML · INJECTABLE · INJECTION
GENTAMICIN SULFATEDiscontinued
GENTAMICIN SULFATE EQ 90MG BASE/100ML · INJECTABLE · INJECTION
GENTAMICIN SULFATEDiscontinued
GENTAMICIN SULFATE EQ 70MG BASE/100ML · INJECTABLE · INJECTION
GENTAMICIN SULFATEDiscontinued
GENTAMICIN SULFATE EQ 2MG BASE/ML · INJECTABLE · INJECTION
GENTAMICIN SULFATEDiscontinued
GENTAMICIN SULFATE EQ 1.6MG BASE/ML · INJECTABLE · INJECTION
GENTAMICIN SULFATEDiscontinued
GENTAMICIN SULFATE EQ 1.2MG BASE/ML · INJECTABLE · INJECTION
GENTAMICIN SULFATEDiscontinued
GENTAMICIN SULFATE EQ 80MG BASE/100ML · INJECTABLE · INJECTION
GENTAMICIN SULFATEDiscontinued
GENTAMICIN SULFATE EQ 60MG BASE/100ML · INJECTABLE · INJECTION
GENTAMICIN SULFATEDiscontinued
GENTAMICIN SULFATE EQ 1.8MG BASE/ML · INJECTABLE · INJECTION
GENTAMICIN SULFATEDiscontinued
GENTAMICIN SULFATE EQ 100MG BASE/100ML · INJECTABLE · INJECTION

Approval history

1993-07-14Labeling · Supplement 6AP
1983-08-11OriginalAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industry →GMP discipline →FDA drug shortages →FDA enforcement & recalls →

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →